Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- JCR, Alexion Pair Up for Neurodegenerative Disease
March 31, 2023
- Twymeeg Tops GP Promotion Ranking 2 Months Running, Belsomra Most Detailed among HPs in February
March 31, 2023
- Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
- Astellas, Roche to Develop Combo Medical Device Solution for Diabetes
March 30, 2023
- Boehringer’s Japan Human Pharma Sales Up 5.6% in 2022
March 30, 2023
- Simulation Driven Decision-Making Support Necessary for R&D Strategy: Astellas Exec
March 29, 2023
- Pfizer Files Tick-Borne Encephalitis Vaccine in Japan
March 29, 2023
- Mochida, Human Life CORD Tie Up on Cell-Based Product in Japan
March 29, 2023
- Estimated 37,746 Patients Given Xocova as of March 19: Shionogi
March 29, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
- Janssen, Labor Union at Odds over Proposed Job Transfers: 2nd Bargaining Session
March 28, 2023
- Santen Files Epinastine Ophthalmic Cream for Allergic Conjunctivitis
March 28, 2023
- Teva Takeda to Copromote Allermist AG with Ceolia
March 28, 2023
- Japanese Man Detained in China was Astellas Employee
March 27, 2023
- Novartis Japan Sees 2023 OK for 1st siRNA Drug for Hyperlipidemia, 7 Approvals to Drive Growth
March 27, 2023
- Takeda Puts Up 100 Billion Yen for New Plasma Therapy Facility in Japan
March 24, 2023
- Ono, Kasawaki-Based AI Platform Firm Tie Up on Antibody Drug Discovery
March 24, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Ono, Macomics Ink Macrophage Drug Discovery Deal
March 24, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…